Pharmacokinetics of Bevacizumab in Three Patients Under the Age of 3 Years with CNS Malignancies

BACKGROUND: Bevacizumab is a recombinant antibody that is increasingly used in pediatric malignancies. The pharmacokinetics of bevacizumab in pediatric patients have been shown to be influenced by tumor localization and body weight. In this report, we present data on the pharmacokinetics and safety...

Descripción completa

Detalles Bibliográficos
Autores principales: Gojo, Johannes, Sauermann, Robert, Knaack, Ursula, Slavc, Irene, Peyrl, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629131/
https://www.ncbi.nlm.nih.gov/pubmed/28577293
http://dx.doi.org/10.1007/s40268-017-0190-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629131/
https://www.ncbi.nlm.nih.gov/pubmed/28577293
http://dx.doi.org/10.1007/s40268-017-0190-z

Ejemplares similares